Follistatin-344 is a synthetic, full-sized version of a naturally occurring protein bearing the same name. Follistatin-344 occurs in two isomers, varying based on their gene splicing. Follistatin may exist endogenously in two distinct variants, referred to as FST 317 and FST 344. The variants are distinguished by their composition: FST 317 comprises 288 amino acids, whereas FST 344 comprises 315 amino acids. The numerical part of their names reflects the number of amino acids in the precursor molecules from which they are synthesized, with the precursor to FST 317 having 317 amino acids and that to FST 344 having 344 amino acids. It appears that FST 344 is the more commonly occurring form across various tissues. On the other hand, the FST 317 variant likely represents a minor fraction, potentially comprising under 5% of the total mRNA transcript related to Follistatin. Thus, Follistatin-344 appears to be the main constituent. Researchers suggest that its primary role may be to counteract the action of the Tumor Growth Factor-beta (TGF-beta) family. The TGF-beta family comprises Myostatin, Activin, and Follicle Stimulating Growth Hormone (FSH). Follistatin-344 appears to stimulate the Insulin/IGF-1 pathway, and the reported immense potential of the peptide has been published in Follistatin-344 research.





Reviews
There are no reviews yet.